Viking Therapeutics Inc

27 oct. 2026, 23:06 UTC

Viking Therapeutics, Inc. traded roughly flat in after-market hours, remaining near the lower end of its one-month range and below its 20-day moving average.

23 oct. 2026, 20:02 UTC

Shares of Viking Therapeutics Inc fell sharply as the company prepares to report earnings on October 28th, breaking a recent trend of higher daily closes.

22 oct. 2026, 20:07 UTC

Viking Therapeutics sees increased bearish sentiment with 6.55k puts traded, 1.6 times expected volume, ahead of its Q3 results on October 28, 2026.

21 oct. 2026, 23:06 UTC

Viking Therapeutics Inc will report its third-quarter financial results on October 28, 2026, and host a conference call at 4:30 p.m. ET.

20 oct. 2026, 23:06 UTC

Viking Therapeutics Inc is trading higher in after-market hours.

19 oct. 2026, 23:41 UTC

Viking Therapeutics Inc shares are modestly higher in after-market trading, reaching their highest point since Monday's close after bouncing back from earlier lows.

16 oct. 2026, 20:02 UTC

Shares of Viking Therapeutics Inc are declining amid a broader downturn in the biotechnology sector, with the SPDR S&P Biotech ETF also lower.

15 oct. 2026, 20:04 UTC

Viking Therapeutics shares advanced after Oppenheimer maintained an "outperform" rating with a $120 price target and UBS initiated coverage with a $94 price target.

14 oct. 2026, 23:02 UTC

Viking Therapeutics shares advanced in after-market trading after UBS initiated coverage with a Buy rating and a price target of $94.00.

13 oct. 2026, 19:51 UTC

Viking Therapeutics Inc shares fell sharply, reaching their lowest point of the day and remaining well below their 20-day moving average.

9 oct. 2026, 20:07 UTC

Viking Therapeutics is seeing increased interest amid reports of a potential bidding war, with speculation about suitors including LLY and positive momentum in the biotech sector.

8 oct. 2026, 20:07 UTC

Shares of Viking Therapeutics Inc declined notably during the session, continuing a downward trend since Wednesday's close, reaching a low before a slight recovery.

7 oct. 2026, 20:08 UTC

Viking Therapeutics Inc shares are trading higher as Truist Securities lowers its price target to $85.00 while maintaining a Buy rating.

6 oct. 2026, 23:01 UTC

Viking Therapeutics Inc has initiated an exploratory oral maintenance dosing study of VK2735, with the stock advancing in after-market trading following the announcement.

5 oct. 2026, 20:06 UTC

Viking Therapeutics Inc shares fell sharply, reflecting a significant decline from a recent high of $43.10, closing down notably since Friday.

2 oct. 2026, 20:07 UTC

Viking Therapeutics Inc shares fell sharply, continuing a decline since Thursday's close and closing significantly below the 20-day moving average.

1 oct. 2026, 23:01 UTC

Viking Therapeutics Inc. is seeing increased social media attention, with its stock rising in after-market trading to $30.51 amid acquisition speculation.

30 sept. 2026, 20:07 UTC

Viking Therapeutics shares are advancing today as discussions on VK2735's weight loss data gain traction, with Cantor setting a $100 price target.

29 sept. 2026, 23:05 UTC

Viking Therapeutics Inc is seeing a modest increase in after-market trading, recovering from an initial low before settling back slightly.

28 sept. 2026, 20:03 UTC

Viking Therapeutics Inc shares fell sharply amid online posts about its VK2735 drug, raising concerns of panic selling despite promising trial results.

25 sept. 2026, 20:02 UTC

Viking Therapeutics shares are lower amid volatility, despite positive trial data, as concerns over a recent capital raise and share sales at $35 persist.

24 sept. 2026, 20:03 UTC

Viking Therapeutics Inc. shares fell sharply after announcing a $500 million capital raise, including 7.86 million shares priced at $35.00 each, amid dilution concerns.

23 sept. 2026, 23:01 UTC

Viking Therapeutics plans to raise $400 million through stock and convertible notes offerings, causing significant after-hours trading decline amid dilution concerns.

22 sept. 2026, 23:01 UTC

Viking Therapeutics Inc gained after Oppenheimer raised its price target for VK2735 from $100 to $120, citing strong trial results and increased retail sentiment.

21 sept. 2026, 23:01 UTC

Viking Therapeutics Inc is advancing in after-market trading following notable social media interest, breaking a streak of ten consecutive lower daily closes.

18 sept. 2026, 20:07 UTC

Viking Therapeutics Inc is declining, continuing a downward trend as the broader market marks its tenth consecutive session of losses.

17 sept. 2026, 19:16 UTC

Viking Therapeutics Inc is trading higher as social media buzz surrounds VK2735 ahead of its anticipated Phase 3 trials, despite recent declines.

16 sept. 2026, 23:06 UTC

Viking Therapeutics Inc is trading modestly higher in after-market hours, following eight consecutive lower daily closes and recent broader market declines.

15 sept. 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher during after-market hours, reflecting broader market trends despite recent economic indicators suggesting a slowdown in manufacturing.

14 sept. 2026, 19:36 UTC

Viking Therapeutics Inc shares are lower, continuing a trend of declines amid broader market weakness and rising crude oil prices affecting sentiment.